What other direction could the stock have gone?
The economic worries gripping the stock market were no match for solid quarterly operating results from the infrastructure leader.
The company reported second-quarter revenue at the low end of its expectations and well below the average Wall Street estimate.
The agricultural leader leaned on its global footprint to overcome historically poor conditions in the U.S. market.
A major insurer agreed to cover one of the company's most important genetic tests.
The company reported a net loss of $120 million for the second quarter, which was much worse than analysts expected.
All eyes were on a new instrument launch, which got off to a strong start judging from pre-orders.
The business is already growing so quickly that it has been grappling with component shortages. What will happen when solar energy really takes off?
The business delivered second-quarter 2019 operating results that beat everyone's expectations -- including its own.
The CRISPR pioneer is taking a slow-and-steady approach to drug development. If peers are overlooking one key element of gene editing, that approach could pay off.
International sales of potash more than made up for stagnant retail profits in the first half of 2019.
The company's slow and steady growth has pushed its stock nearly 40% higher since the start of the year.
The company announced second-quarter 2019 operating results and pledged to be more efficient.
Sanofi is walking away from an important collaboration, leaving shareholders wondering what's next.
Air Products & Chemicals, Ecolab, and McCormick generate gobs of cash, pay handsome dividends, and are likely to survive for decades to come.
Higher collection and disposal revenue drove the growth and pushed operating cash flow over the $1 billion mark.
A drug candidate was oh-so-close to a regulatory decision, but next month's meeting has been delayed indefinitely.
Investors have high hopes for the $2.7 billion gene editing pioneer, yet there are reasons for both optimism and pessimism.
The gene-editing approach might prove more useful outside the clinic.
Wall Street is not sold on the latest clinical results.